| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1481 | 2021 |
| The MAPK pathway across different malignancies: a new perspective M Burotto, VL Chiou, JM Lee, EC Kohn Cancer 120 (22), 3446-3456, 2014 | 1102 | 2014 |
| Pseudoprogression and immune-related response in solid tumors VL Chiou, M Burotto Journal of Clinical Oncology 33 (31), 3541, 2015 | 915 | 2015 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ... ESMO open 5 (6), e001079, 2020 | 534 | 2020 |
| The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses V Prasad, C Kim, M Burotto, A Vandross JAMA internal medicine 175 (8), 1389-1398, 2015 | 407 | 2015 |
| Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma MS Van Der Heijden, G Sonpavde, T Powles, A Necchi, M Burotto, ... New England Journal of Medicine 389 (19), 1778-1789, 2023 | 243 | 2023 |
| Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label … RJ Motzer, T Powles, M Burotto, B Escudier, MT Bourlon, AY Shah, ... The Lancet Oncology 23 (7), 888-898, 2022 | 239 | 2022 |
| Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma RJ Motzer, DF McDermott, B Escudier, M Burotto, TK Choueiri, ... Cancer 128 (11), 2085-2097, 2022 | 225 | 2022 |
| Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins MS Poruchynsky, E Komlodi-Pasztor, S Trostel, J Wilkerson, M Regairaz, ... Proceedings of the National Academy of Sciences 112 (5), 1571-1576, 2015 | 198 | 2015 |
| Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials M Burotto, EE Manasanch, J Wilkerson, T Fojo The oncologist 20 (4), 400-410, 2015 | 174 | 2015 |
| 696O_PR Nivolumab+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial TK Choueiri, T Powles, M Burotto, MT Bourlon, B Zurawski, VMO Juárez, ... Annals of Oncology 31, S1159, 2020 | 161 | 2020 |
| Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma TK Choueiri, T Powles, L Albiges, M Burotto, C Szczylik, B Zurawski, ... New England Journal of Medicine 388 (19), 1767-1778, 2023 | 118 | 2023 |
| Bendamustine and rituximab in relapsed and refractory hairy cell leukemia M Burotto, M Stetler-Stevenson, E Arons, H Zhou, W Wilson, RJ Kreitman Clinical Cancer Research 19 (22), 6313-6321, 2013 | 102 | 2013 |
| Nivolumab+ cabozantinib (NIVO+ CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended … RJ Motzer, TK Choueiri, T Powles, M Burotto, MT Bourlon, JJ Hsieh, ... Journal of Clinical Oncology 39 (6_suppl), 308-308, 2021 | 85 | 2021 |
| Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label … D Cella, RJ Motzer, C Suarez, SI Blum, F Ejzykowicz, M Hamilton, ... The Lancet Oncology 23 (2), 292-303, 2022 | 80 | 2022 |
| Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy M Burotto, JG Gormaz, S Samtani, N Valls, R Silva, C Rojas, S Portiño, ... Seminars in oncology 45 (3), 164-169, 2018 | 79 | 2018 |
| Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? A Renner, M Burotto, C Rojas Journal of Global Oncology 5, 1-5, 2019 | 78 | 2019 |
| Biomarkers in early-stage non–small-cell lung cancer: current concepts and future directions M Burotto, A Thomas, D Subramaniam, G Giaccone, A Rajan Journal of Thoracic Oncology 9 (11), 1609-1617, 2014 | 73 | 2014 |
| Ethanol inhibits L-arginine uptake and enhances NO formation in human placenta CG Acevedo, G Carrasco, M Burotto, S Rojas, I Bravo Life sciences 68 (26), 2893-2903, 2001 | 73 | 2001 |
| 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab+ ipilimumab (N+ I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) RJ Motzer, NM Tannir, DF McDermott, M Burotto, TK Choueiri, ... Annals of Oncology 32, S685-S687, 2021 | 70 | 2021 |
